Conference
Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After >= 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib
Authors
Hughes TP; Lipton JH; Leber B; Spector N; Cervantes F; Pasquini R; Clementino N; Schwarer AP; Mahon F-X; Rea D
Volume
118
Pagination
pp. 278-278
Publisher
AMER SOC HEMATOLOGY
Publication Date
November 18, 2011
Name of conference
53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
Conference place
San Diego, CA
Conference start date
December 10, 2011
Conference end date
December 13, 2011
Conference proceedings
BLOOD
Issue
21
ISSN
0006-4971